BioLife Solutions (BLFS) stock surged 5.10% in intraday trading on Tuesday, following the release of its Q4 2024 earnings report and positive financial guidance for 2025.
The life sciences company posted impressive results for the fourth quarter and full year 2024, with significant improvements in key financial metrics. Highlights included:
The company's strong performance was driven by the successful divestiture of non-core product lines, resulting in a leaner and more focused business. BioLife Solutions also provided optimistic guidance for 2025, projecting revenue between $95.5 million and $99 million, representing 16% to 20% growth over 2024. This growth is expected to be fueled by the company's cell processing platform, with anticipated revenue of $86.5 million to $89 million, an 18% to 21% increase from the previous year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.